Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

AMULET IDE: New Research Compares WatchMan and Amulet Devices Providing New Evidence

Recently, at the TCT Congress results from the SWISS-APERO study comparing Watchman and Amulet devices were presented. Now, a new study, Amulet IDE—published in Circulation—, compared both devices on a large number of patients.

AMULET Die: Un nuevo estudio compara los dispositivos Watchman y Amulet y arroja nueva evidencia

Amulet IDE was designed to evaluate the safety and efficacy of dual-seal mechanism device Amulet compared with the Watchman (a widely used tool in clinical practice).

In this sense, the Amulet device was non-inferior in terms of safety and efficacy to prevent stroke in patients with nonvalvular atrial fibrillation compared with the Watchman device. Atrial appendage occlusion was superior with Amulet—a result also observed in SWISS-APERO.

In this study, 1878 patients with nonvalvular atrial fibrillation and at high risk of stroke were randomized to receive either device. The primary safety endpoint was a composite of procedure-related complications, all-cause mortality, or major bleeding.

The efficacy endpoint was a composite of ischemic stroke or systemic embolism at 18 months. Atrial appendage seal at 45 days was also considered.

In terms of safety, Amulet proved to be non-inferior to Watchman (14.5% vs. 14.7%; p < 0.001).


Read also: TCT 2021 | SWISS-APERO: Difference in Leaks between the Amulet and the Watchman.


However, results were similar for major bleeding and death (10.6% vs. 10.0%, and 3.9% vs. 5.1%, respectively).

Procedure-related complications (pericardial effusion and device embolization) were higher with Amulet (4.5% vs. 2.5%).

Conclusion

The Amulet atrial appendage occluder device was non-inferior in terms of safety and efficacy for stroke prevention in patients with nonvalvular atrial fibrillation. Peri-procedural complications were higher with Amulet, but decreased with increased operator experience.

Original Title: Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE).

Reference: Dhanunjaya Lakkireddy et al. Circulation. 2021 Nov 9;144(19):1543-1552. doi: 10.1161/CIRCULATIONAHA.121.057063.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...